SynthesisFrontiers in immunology2025
Bibliometric and visual analysis of global crc circular RNA research 2015-2023.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exosomal circPOLK promotes metastasis of NSCLC cells via regulating mir-1204/SOX8 axis.Cancer cell international · 2026Article
- Potential treatment benefits of a GLP-1R antagonist in combination with immune checkpoint inhibitors in colorectal cancer.Oncology letters · 2026Article
- Global research hotspots and trends in microglia in ischemic stroke.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is the third highest malignant tumor in the world in terms of incidence rate, accounting for about 10% of all cancer cases and the second leading cause of cancer related deaths. Timely diagnosis and effective treatment are key to significantly improving the survival rate of CRC patients. Various factors including gender, environmental factors, lifestyle choices, and genetic predisposition are all causes of the onset of CRC. Circular RNA(circRNA) mainly exists in cancer cells and tissues, solid tumors, peripheral blood, exosomes, and body fluids (such as serum, plasma, and saliva). Due to their resistance to degradation and presence in body fluids, CircRNA is non-invasive and an ideal candidate for liquid biopsy, thus having high diagnostic potential. Current research has found that circRNA can regulate the proliferation, migration, invasion, and apoptosis of CRC cells. Methods: This article aims to comprehensively evaluate the current status and trends of circRNA research in the field of CRC through bibliometric analysis. Intended to use software tools such as VOSviewer, CiteSpace, Microsoft Excel, and R language package to illustrate research progress and focus, in order to outline development trends and future research directions. Results: This study used specific inclusion and exclusion criteria to investigate 1048 papers published before December 31, 2023 in the core database of the World Council for Scientific Knowledge. Our research findings indicate that China has the highest number of published papers in this field, with Nanjing Medical University and Kiavash Hushmandi considered the most influential institutions and authors. The Journal ofOncology Frontiers is the journal with the most published papers, while the article "Circular RNA: The New Star of Non coding RNA" is the journal with the most published papers. In addition, terms such as "signaling pathway", "promoting metastasis", "promoting proliferation", and "drug resistance" have become important focuses in this research field. Conclusions: This study indicates that the focus between circRNA and CRC has shifted from studying the biological characteristics of circRNA to studying the regulation of circRNA molecular mechanisms. Future research should emphasize the potential use of circRNA as a biomarker for the diagnosis, prognosis, and treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.